Skip to main content
Fig. 7 | BMC Cardiovascular Disorders

Fig. 7

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

Fig. 7

Forest Plot for All Medication Discontinuation and Discontinuation Due to Side Effects. Individual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for randomized controlled trials (RCTs) comparing colchicine to placebo or control in patients with various cardiac conditions. The pooled RRs with 95 % CI were calculated using random-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95 % CI for each trial’s RR. The diamonds signify the pooled RR; the diamond’s centre denotes the point estimate and width denotes the 95 % CI. Including only data from the 7 RCTs that reduced the dose of colchicine for intolerance or body weight <70 kg [18–22, 24, 25], the rates of medication discontinuation were still increased: discontinuation overall, RR 1.40, 95 % CI 1.04-1.89, p = 0.03, I2 = 0 %; 7 RCTs, n = 1524; and discontinuation due to adverse events, RR 2.22, 95 % CI 1.08-4.56, p = 0.03, I2 = 0 %; 4 RCTs, n = 684. There were no differences in medication discontinuation overall or discontinuation due to adverse events between subgroups of cardiovascular disease, pericarditis, and post-pericardiotomy or radiofrequency ablation patient trials (interaction p = 0.16-0.18) (results not shown)

Back to article page